Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 3/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9082663 | 0.87 | CMA1 (0.43) | BRD4PGRCMA1AHRPNMT | |
| SCHEMBL7414360 | 0.81 | HTR5A (0.41) | PGRADRA2AADRA2BADRA2CPARP10 | |
| SCHEMBL7414456 | 0.80 | AHR (0.43) | PGRCMA1AHRPNMTADRA2A | |
| SCHEMBL31076226 | 0.79 | BRD4 (0.41) | BRD4PGRCMA1AHRPNMT | |
| Hydrochloric Acid SCHEMBL7420730 | 0.79 | MAP2K2 (0.38) | BRD4PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL17027185 | 0.77 | HPGD (0.48) | MEN1KMT2AGAAL3MBTL1KDM4E | |
| SCHEMBL17027111 | 0.77 | KIF11 (0.35) | ADRA2AADRA2BADRA2CMEN1KMT2A | |
| SCHEMBL20870462 | 0.77 | HPGD (0.40) | BRD4MEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL31394401 | 0.77 | BRD4 (0.46) | BRD4PGRCMA1AHRPNMT | |
| SCHEMBL17026918 | 0.76 | TDP2 (0.39) | PNMTTDP2PARP10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688791-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-02-11 | — | — | EP | disclosed |
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-12-11 | — | — | US | disclosed |
| US-12247036-B2 | Tricyclic compounds for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20240417410-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4469164-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024208934-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-10-10 | — | — | WO | disclosed |
| WO-2024169914-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-08-22 | — | — | WO | disclosed |
| US-8946212-B2 | Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2015-02-03 | — | — | US | disclosed |
| EP-2288604-B1 | ANNELATED N-HETEROCYCLIC SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2014-01-08 | — | — | EP | disclosed |
| US-20120122853-A1 | ANNELATED N-HETEROCYCLIC SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2012-05-17 | — | — | US | disclosed |
| EP-2288604-A1 | ANNELATED N-HETEROCYCLIC SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009149820-A1 | ANNELATED N-HETEROCYCLIC SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
| EP-0815103-A1 | TRYPSIN AND THROMBIN INHIBITORS | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122853-A1 | ANNELATED N-HETEROCYCLIC SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | PPARD, PPARA, PPARG | BRD4 2159/4885PGR 1578/4885CMA1 4789/4885 |
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | BRD4 245/4885PGR 333/4885CMA1 3100/4885 |
| US-20240417410-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | BRD4 245/4885PGR 333/4885CMA1 3100/4885 |
| US-12247036-B2 | Tricyclic compounds for the treatment of cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | BRD4 245/4885PGR 333/4885CMA1 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.